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Abstract 
Sex-based differences influence incidence and outcome of infectious disease. Women have a 
significantly greater incidence of urinary tract infection (UTI) than men, yet, conversely, male 
UTI is more persistent with greater associated morbidity. Mechanisms underlying these sex-
based differences are unknown, in part due to a lack of experimental models. We optimized a 
model to transurethrally infect male mice and directly compared UTI in both sexes. Although 
both sexes were initially equally colonized by uropathogenic E. coli, only male and testosterone-
treated female mice remained chronically infected for up to 4 weeks. Female mice had more 
robust innate responses, including higher IL-17 expression, and increased γδ T cells and group 3 
innate lymphoid cells in the bladder following infection. Accordingly, neutralizing IL-17 
abolished resolution in female mice, identifying a cytokine pathway necessary for bacterial 
clearance. Our findings support the concept that sex-based responses to UTI contribute to 
impaired innate immunity in males and provide a rationale for non-antibiotic-based immune 
targeting to improve the response to UTI. 
  
Introduction 
Mounting evidence points to the importance of sex in determining susceptibility to infection and immune 
responses (1-3). For instance, sex-specific differences are evident in bacterial infections by Legionella, 
Mycobacterium, and Campylobacter (2). Urinary tract infections (UTI) exhibit one of the most distinctive 
sex differences among infectious diseases; adult premenopausal women are 40 times more likely than 
adult men to experience UTI (4). Consequently, basic and clinical research has overwhelmingly focused 
on the pathogenesis of UTI in females with little regard for the underlying reasons for this disparity. 
Importantly, this bias in adult women is not representative of the overall prevalence of UTI in the general 
population. Indeed, the incidence of UTI is similar between the sexes in infants and the elderly (5). For 
example, 40% of pediatric UTI patients (<24 months of age) are male (6). Similarly, the incidence of UTI 
was 14% in women and 11% in men in a healthy geriatric population over the age of 65 (7). These 
changes in incidence suggest that factors such as sex hormone levels might influence susceptibility to 
infection during a lifetime (3). Notably, although the incidence of male UTI in adulthood is significantly 
lower compared to adult women, male UTI patients have an elevated risk of morbidity from 
complications, as infection in men of all ages is clinically classified as a complicated UTI (8-10). Indeed, 
although the same first-line antibiotics are used in female and male patients, men require longer treatment 
durations to eradicate bacteria (11). Together, increased severity and treatment challenges, combined with 
mounting antibiotic resistance in uropathogenic E. coli (UPEC) strains, highlight the need to better 
understand immunity to UTI in women and men, to determine the mechanisms mediating disease 
outcome in both sexes. In turn, this knowledge may contribute to the development of non-antibiotic based 
stratified therapies targeting sex-specific immune pathways for the treatment of women and men with 
UTI. 
 
Given the frequency and high morbidity of UTI in infant and elderly males, it is disconcerting that our 
knowledge of UTI pathogenesis is based almost entirely on studies in female animals. Indeed, 
transurethral instillation models used to study UTI are performed almost exclusively in female rodents 
(12-14), and the technique is broadly reported to be unachievable in male animals (15-19). Only a small 
number of laboratories report the use of transurethral instillation of bacteria into the male urogenital tract. 
Studies from these groups investigate prostatitis, and no report has included quantification of bacterial 
colonization in the bladder or comparison to infected female animals (20-26). To date, only one animal 
study explored sex differences in UTI, by surgically exposing the bladder abdominally and injecting 
bacteria through the bladder wall to establish infection (27). The authors observed that male C3H/HeN 
mice, but not C57BL/6J mice, remain chronically infected following infection (27). Importantly, 
however, in this model it cannot be excluded that surgery-related inflammation and secondary effects of 
wound-healing pathways, known to differ between the sexes (28-30), influenced bacterial clearance. 
 
Thus, to test the hypothesis that divergent host responses to UTI between male and female animals results 
in differential outcomes following infection with UPEC, we established a method of intravesical 
instillation of bacteria via catheterization of the urethra of male mice (31). This protocol, derived from 
one routinely used for female UTI studies (12), permitted direct comparison of the innate and adaptive 
immune response in infected female and male animals over time. C57BL/6J female mice resolved their 
infection without intervention, as previously reported (32, 33), however male mice displayed persistent 
bacteriuria, remaining chronically infected for at least one month. Within the first 24 hours following 
infection, female mice exhibited more robust cytokine expression accompanied by greater immune cell 
infiltration. Cytokine expression, immune cell infiltration, and resolution were attenuated or abrogated in 
testosterone-treated female mice. These findings suggest that the increased severity associated with male 
UTI is due to hormone-mediated suppression of the innate immune response.  
 
Results  
Male mice fail to resolve UPEC infection 
To directly compare transurethrally infected female and male animals, we adapted a protocol to 
catheterize female mice to male animals (12). A detailed video protocol of our method is reported 
elsewhere (31). To investigate the capacity of female and male mice to resolve UPEC infection, we 
intravesically instilled 7 week old C57BL/6J mice of both sexes with 107 colony forming units (CFU) of 
one of two isogenic UPEC UTI89 strains bearing resistance to ampicillin (UTI89-GFP-ampR) or 
kanamycin (UTI89-RFP-kanR) (32). Strikingly, we observed that a majority of male mice remained 
chronically infected up to one month, as determined by the presence of UPEC in the urine, in contrast to 
female mice, which resolved infection (Figure 1A). We sacrificed experimental groups at predetermined 
timepoints to quantify bladder bacterial burden. While female and male mice were equally colonized at 24 
and 48 hours post-infection (PI), bacterial burden decreased over time in female mice but remained 
elevated in male mice, resulting in statistically significantly higher bacterial burdens in male mice 28 days 
PI (Figure 1B). At 28 days PI, 100% of female mice (21/21), but only 29% (7/24) of male mice had 
sterile urine (percentages calculated from animals shown in Figure 1B). Importantly, female mice that 
resolve an acute infection have no UPEC in their urine but maintain bacterial burdens of approximately 
103 CFU in quiescent tissue reservoirs in C57BL/6J mice (Figure 1B, 28 days PI) (32, 33). In a female 
UTI model, infection is not confined to the bladder and the kidneys can be colonized by vesicoureteral 
reflux (34). To determine the extent of infection in male mice, we infected mice with 107 CFU UTI89-
GFP-kanR and assessed bacterial colonization 60-90 minutes PI. Bacterial CFU in male mice were 
comparable to CFU previously reported in female mice at the same timepoint (Figure S1A) (35). UPEC 
also colonized the prostate, kidneys, seminal vesicles, preputial glands, and testes in a majority of mice at 
this timepoint (Figure S1A). Over time, kidney colonization was equivalent between the sexes until 14 
days PI, when CFU declined in female mice and increased in male mice (Figure S1B). Finally, in male 
mice, the prostate, seminal vesicles, preputial glands, and testes were colonized for at least 14 days 
(Figure S1C). 
 
Female and male mice mount a nonsterilizing adaptive immune response to UTI 
We previously reported that female mice develop a nonsterilizing adaptive immune response following 
primary UTI that is abrogated in female Rag2-/- mice (32). Whereas bacterial burden is reduced 2-3 logs 
in wildtype mice following challenge infection compared to primary UTI, bacterial burden in Rag2-/- mice 
is equivalent following primary and challenge infection. Indeed, female Rag2-/- animals can resolve a 
primary UTI, suggesting that adaptive immunity is dispensable for bacterial clearance (32). Based on this 
observation, it was unlikely that a failure to mount an adaptive immune response could explain why 
chronic infection developed in male mice. To experimentally rule out this possibility, we employed a 
model of challenge infection (Figure 1C) (32). Female and male mice were infected with 107 CFU of 
UTI89-GFP-ampR and a cohort of each sex was sacrificed at 24 hours PI. Although 20/21 female animals 
had sterile urine, compared to only 3/18 male mice, we treated both sexes beginning at 29 days PI with 
trimethoprime-sulfamethoxazole (TMP-SMX, Avemix) in the drinking water, to control for potential 
influence of antibiotic treatment (Figure 1C). Following a 5 day antibiotic treatment and a subsequent 7 
day wash-out period, mice were confirmed to have sterile urine and then infected with the isogenic UPEC 
strain, UTI89-RFP-kanR. Comparable to that observed in Figure 1B, bacterial burden was not different 
between female and male mice 24 hours post primary infection (Figure 1D). As we previously reported, 
bacterial burden was significantly lower in female mice 24 hours post challenge infection compared to 
primary infection, and as hypothesized, bacterial burden was also significantly reduced in male mice 
following challenge infection (Figure 1D). Bacterial burden in challenged animals was not statistically 
significantly different between the sexes, suggesting that both female and male mice mount an adaptive 
immune response capable of reducing but not eliminating bacterial burden following a challenge 
infection. 
 
Female mice exhibit greater cytokine responses to UTI than male mice 
The results of our challenge infection experiments ruled out the possibility that a weak or absent adaptive 
immune response accounted for differences in resolution of UTI between the sexes. In addition, as female 
Rag2-/- mice, lacking T and B cells, or T cell depleted mice resolve primary infection with the same 
kinetic as wildtype female mice (32), we reasoned that the failure to resolve infection in male mice was 
due to differences in an innate mechanism. To identify innate host factors contributing to resolution in 
female mice or chronic infection in male mice, we assessed cytokine expression at 24 and 48 hours PI, 
which is the peak of the cytokine response in female mice (35). Female and male mice were instilled with 
PBS or infected with UPEC strain UTI89-GFP-ampR or UTI89-RFP-kanR as above, and 32 cytokines 
were analyzed using Luminex multianalyte analysis on whole bladder tissue homogenates at 24 and 48 
hours PI. Twenty-six cytokines were expressed above the minimum detectable concentration plus 2 
standard deviations in bladders in at least one condition. 23/26 analytes measured were significantly 
different (T-test, false discovery rate adjusted p value: q<0.05) between PBS-instilled and UPEC-infected 
female mice at 24 hours PI (Table 1). By contrast, only 7/26 analytes were statistically significantly 
different between control PBS-treated and UPEC-infected male animals (Table 1, T-test, q<0.05). 
ANOVA revealed that 21/26 analytes were significantly differentially expressed among the four groups 
of PBS-treated and UPEC-infected female and male mice (Table 1, q<0.05). To have a global view of the 
relative expression pattern of these 21 cytokines in the four treatment groups, we used unsupervised 
hierarchical clustering and found that UPEC-infected females exhibited the highest cytokine expression at 
24 hours PI, whereas infected male mice clustered more closely to PBS-treated animals of both sexes than 
infected female mice (Figure 2A). The absolute protein expression levels of the 23 cytokines listed in 
Table 1 (PBS vs. UTI female mice) were, overall, greater in infected female animals compared to 
infected male mice and PBS-treated mice of both sexes at 24 hours PI (Figure 2B). This differential 
response was short-lived, as female and male mice had, with a few notable exceptions, similar cytokine 
levels at 48 hours PI, which approached levels comparable to those measured in naïve, untreated bladders 
(Figure 2C). These differences in cytokine expression were unexpected, as bacterial colonization was 
equivalent at 24 and 48 hours PI between the sexes (Figure 1B).  
 
To determine whether this distinct pattern of cytokine expression might be relevant in the context of 
human infection, we took advantage of a publically available dataset (Dataset S1 from ref (36)) from a 
recently published study describing the impact of age, sex, and genetics on transcriptional variation in 
induced human immune responses (36). Using this dataset, we investigated differences in gene expression 
between 300 women and 300 men aged 20-49 (to avoid potential cofounding effects in post-menopausal 
women), following ex vivo whole blood stimulation with E. coli. We observed that 49% (275/560) of the 
immune genes measured showed a significant (n=600, q<0.01) sex association, which can be globally 
viewed in a principle component analysis (PCA) (Figure 2D, Table S1 lists all 275 genes represented in 
this PCA plot). The expression levels of 4 of these differentially expressed genes, CXCL2, IL-8, IL-1α, 
and LIF, were overlaid on the PCA plot of all differentially expressed genes shown in Figure 2D, 
illustrating that these cytokines showed higher expression (red color) in female donors and lower 
expression (green color) in male donors after E. coli stimulation (Figure 2E), similar to the pattern 
observed in mice. Also mirroring our observations in the mouse model, CCL3, IL-4, and IL1β (Table 
S1), were all significantly (q<0.01) higher in female donors as compared to male donors after stimulation. 
A sex-association with the expression of IL-4R and IL-13R (higher in females), as well as other receptors 
for cytokines differentially expressed in our mouse model, was also observed (Table S1), which would be 
expected to influence how circulating cells expressing these receptors respond to their cognate cytokines. 
Together, these findings directly support the potential clinical relevance of our findings in this mouse 
model.  
 
Immune cell infiltration is greater in infected female mice  
Many of the cytokines induced during UTI facilitate the recruitment of innate immune cells to the site of 
infection (37). To test whether the divergent cytokine response between the sexes impacted immune cell 
infiltration, we infected female and male mice with UPEC strain UTI89-RFP-kanR and analyzed bladder 
tissue by flow cytometry at 24 and 48 hours PI. Infected bladders from female mice had significantly 
greater numbers of total CD45+ immune cells compared to infected male mice (Figure 3A), correlating 
with increased cytokine expression at 24 hours PI (Figure 2A-B). Similar to cytokine expression, this 
difference was evident only at 24 hours PI. While tissue-resident macrophages were not different between 
the sexes or between naïve and infected animals at these early timepoints, female mice had significantly 
higher numbers of dendritic cells (DCs) at 24 hours PI (Figure 3B). This increase was modest and did not 
account for the overall increase in CD45+ immune cell populations. By far, the most numerous immune 
cells were infiltrating neutrophils, monocyte-derived cells, and eosinophils, which were all significantly 
increased in female mice compared to male mice, only at 24 hours PI (Figure 3C, Figure S2A-B shows 
gating strategy). Differences in immune cell numbers were not due to baseline differences in naïve 
bladder resident immune cell populations, as flow cytometric analysis of uninfected bladder tissue 
revealed that the immune cell compartment was not different between female and male mice (Figure 3A-
C, 0 hours PI).  
 
Bacterial uptake is altered in male mice  
Previously, we reported that bacteria are found predominantly in resident macrophages at 4 hours PI and 
are distributed among all phagocytic cells at 24 hours PI in female mice (32). As neutrophils and 
monocyte-derived cells phagocytose significant numbers of bacteria in female mice (32), we reasoned 
that the reduced immune cell infiltration in male mice would lead to altered bacterial uptake. To test this 
hypothesis, we infected female and male mice with UPEC strain UTI89-RFP-kanR and analyzed bladders 
by flow cytometry 24 hours PI to assess the identity and the number of phagocytes containing bacteria. To 
have a global view of UPEC-infected cells, we overlaid traditionally gated populations on a tSNE plot of 
concatenated infected bladder samples (Figure 4A-B). We then visualized UPEC-containing immune 
cells using the same tSNE-generated parameters in female or male bladders, observing that overall, UPEC 
distribution was similar, but female mice had more infected cells compared to male mice (Figure 4C), 
which was surprising given that similar numbers of UPEC CFU were present in female and male bladder 
tissue at 24 hours PI (Figure 1B). We quantified the number of infected cells and observed that the 
majority of UPEC+ immune cells were neutrophils and monocyte-derived cells in both sexes at 24 hours 
PI (Figure S2C-D shows gating strategy, Figure 4D, MHC II+ and MHC II- monocyte-derived cells are 
combined in one graph). Compared to female mice, however, male animals had fewer UPEC+ monocyte-
derived cells, UPEC+ resident macrophages, and UPEC+ DCs at 24 hours PI (Figure 4D). To test whether 
differences in the number of UPEC+ cells was a result of differential phagocytic capacity between the 
sexes, we assessed the percentage of UPEC+ cells among defined immune cell populations. While 
equivalent percentages of neutrophils and monocyte-derived cells contained UPEC in both sexes, female 
mice had a greater percentage of UPEC+ resident macrophages and DCs compared to male mice, 
suggesting that the phagocytic capacity of professional APCs may be different between the sexes (Figure 
4E).  
 
Testosterone abrogates immunity to UTI in female mice 
As hormones are major drivers of sexual dimorphism, we hypothesized that testosterone was responsible 
for the observed sex difference in bacterial clearance. To specifically test this, we castrated or sham-
castrated 7 week old male mice to eliminate the primary source of testosterone, and allowed a 1 week 
recovery period before infection with UPEC. Resolution of infection was measured by monitoring for the 
presence of bacteria in urine, and at 28 days PI, bacterial titers were measured in the bladder. We 
observed no significant differences in bacterial clearance over time or in bacterial burden between mock-
treated or castrated mice (Figure 5A-B), although testosterone levels were efficiently decreased in 
castrated male mice (Figure 5C). 
 
To address the question of whether estrogen augmentation was needed concurrently with testosterone 
elimination to resolve infection, we infected male mice that were castrated and then supplemented with 
slow-release estradiol pellets, and followed bacterial clearance over time. After 28 days of infection, 8/12 
mock-castrated mice, 5/8 castrated/placebo-treated mice, and 4/5 castrated/estradiol-supplemented mice 
were still infected, demonstrating that estrogen-supplementation did not improve the capacity to resolve 
UTI (Figure 5D). All groups had similar bacterial burdens at 28 days PI (Figure 5E). Complicating 
interpretation, castration combined with estradiol supplementation resulted in significant mortality, in 
which 4/12 castrated/estradiol-supplemented mice died prior to or immediately after infection and in the 
remaining animals, anatomical changes, which only arose in animals supplemented with estradiol, made 
catheter insertion extraordinarily difficult or impossible, such that 3 of the remaining 8 mice could not be 
infected. 
 
We next tested the impact of testosterone in female mice using slow-release silastic tubes filled with 
testosterone or left empty as a control. Animals were permitted to recover 1 week after subcutaneous 
implantation of tubes before infection with UPEC and bacteriuria was followed over 28 days. 
Testosterone implantation uniformly elevated plasma testosterone levels in female mice to within the 
range observed in male mice (Figure 5C). Strikingly, testosterone-treated female mice failed to resolve 
infection and had persistent bacteriuria for the duration of the experiment, whereas all mock-treated 
animals had sterile urine by 28 days PI (Figure 5F). Additionally, although testosterone treatment did not 
alter bacterial burden at 24 hours PI between the two groups (Figure 5G), testosterone-treated mice had 
significantly elevated bladder bacterial burden compared to control mice at 28 days PI, similar to that 
observed in male mice (Figure 5H). As testosterone can be aromatized to estrogen (38), we measured 
serum levels of estrogen in testosterone-treated female mice, observing that estrogen levels were not 
elevated above levels in naive or mock-tube implanted female mice (Figure 5I). We assessed cytokine 
expression at 24 hours PI, observing that, similar to infected male mice, testosterone-treated female mice 
appeared to have lower overall absolute cytokine expression levels compared to control female animals 
implanted with empty tubing (Figure 5J). Due to the lower number of samples (n=12/group), which 
limited the power in this study, statistical analysis and correction for multiple testing revealed that 9/26 
analytes were significantly differently expressed (q<0.15, Figure 5K, Table 2) between the two groups. 
CCL11 (eotaxin), was among these cytokines, and accordingly, diminished expression correlated with a 
decrease in eosinophil infiltration in testosterone-treated mice (Figure 5L). No differences in cellular 
infiltration were observed for any other cell type between mock-treated and testosterone-treated female 
mice 24 hours PI (Figure S3A). Finally, we were surprised to observe that bacterial uptake, by any cell 
type, was not altered in persistently infected, testosterone-treated female mice at 24 hours PI (Figure 
S3B), suggesting that chronicity is not directly mediated by reduced phagocytosis early in infection. 
 
Female mice develop an immune response characteristic of type II immunity 
IL-4, IL-5, and IL-13 were significantly elevated in female mice compared to male mice during infection 
and IL-4, IL-9, and IL-13 were more highly expressed in control female mice compared to those treated 
with testosterone (Figure 2 and Figure 5). In addition, female mice had greater numbers of eosinophils 
infiltrating infected tissue compared to male mice and testosterone-treated female mice (Figure 5L). 
Therefore, we hypothesized that female mice initiate a type II immune response mediating resolution of 
infection that is not induced in male mice. We first tested whether ablation of eosinophils, by 
administration of α-SiglecF antibody (39), impacted resolution of infection. Despite reducing the number 
of circulating eosinophils by 60-70% (Figure S4A), depleting antibody treatment did not alter the kinetic 
of resolution in female or male animals over 28 days (Figure S4B) or the development of an adaptive 
immune response (Figure S4C). 
 
We then tested upstream mediators of type II immunity. Type II immunity can be initiated by damage to 
an epithelial cell layer, which is a hallmark of UTI (40). Damage results in the release of alarmins, 
including TSLP, IL-25, and IL-33, which induce IL-4, IL-5, IL-9, and IL-13 expression, alternative 
macrophage activation, and innate lymphoid cell (ILC) activation or expansion (41-43). We measured IL-
33 and IL-25 expression in bladder tissue finding that, remarkably, IL-33 expression was nearly three 
times higher in female mice compared to male mice at 24 hours PI (Figure 6A). IL-25 was not detected in 
naïve or infected bladder tissue from either sex. Bladder resident macrophages from female mice 
upregulated IL-4Rα, which is associated with alternative activation (44), to a greater extent than in male 
mice during infection (Figure 6B). Additionally, the number of bladder-associated ILCs, defined as 
CD90+ CD3- CD4- NK1.1- MHC II- CD11b-, increased only in female mice 24 hours PI when compared 
to naïve animals (Figure 6C).  
 
We reasoned that exogenous IL-33 would promote resolution of infection in male mice. Male mice were 
infected and IL-33 was administered directly into the bladder at the time of infection and 24 hours PI 
(Figure S5A). No differences in resolution were observed between the treated and control groups (Figure 
S5B). In addition, IL-33 supplementation did not impact bacterial burden between treated and control 
animals following primary or challenge infection (Figure S5C). We also tested whether neutralizing IL-
33 in female mice would impair bacterial clearance or innate immune responses (Figure S5A) (45). 
Female mice, treated with an α-IL-33 antibody 2 hours prior to infection and 1, 4 and 7 days PI, resolved 
their infection with similar kinetics and had no differences in bacterial burden following primary or 
challenge infection compared to isotype-treated mice (Figure S5D-E). At 24 hours PI, treated and control 
female mice showed no differences in the number of resident immune cells, infiltrating myeloid cells, or 
lymphocytes as compared to isotype-treated mice (Figure S5F). The number of UPEC+ immune cells was 
also not different between the groups (Figure S5G). Supporting that type II immune responses were not 
directly responsible for bacterial clearance, we observed no differences between control and testosterone-
treated female mice with respect to IL-33 expression, macrophage IL-4Rα expression, or number of ILCs 
in infected bladder tissue 24 hours PI (Figure 6D-F), despite that testosterone treatment abrogated the 
capacity to resolve infection in female mice. 
 
IL-17 is necessary but not sufficient for resolution of UTI 
Having ruled out a role for type II immunity in bacteria clearance, we considered whether other immune 
cell populations contributed to resolution. In the course of our investigations, we also quantified 
lymphocytic populations accumulating in the bladder during UTI. We observed that CD3+CD4+ T cells, 
NK cells, γδ T cells, and CD4+ ILC3 (LTi-like cells, CD90+ CD25+ CD4+ CD3- NK1.1- MHC II- CD11b-) 
were similar in number between naïve female and male mice, with the exception of γδ T cells (Figure 
7A). These same populations were statistically significantly increased only in infected female mice at 24 
hours PI, whereas these cell populations were not different between naive and infected male mice (Figure 
7A). Consistent with this observation, these cell populations were decreased in testosterone-treated female 
mice compared to control-treated mice (Figure 7B). Our previous work ruled out a role for T cells in 
bacterial clearance (32), therefore, we infected female wildtype and Rag2-/-γc mice, which lack NK cells 
and ILCs, and followed resolution of infection over time. Remarkably, Rag2-/-γc mice remained infected 
up to 80 days PI, whereas wildtype female mice resolved their infection within 1 month (Figure 7C). Of 
note, Rag2-/-γc mice have eosinophils, supporting our conclusion that these cells do not mediate resolution 
of infection. To specifically test the contribution of NK cells, we infected wildtype female mice treated 
with a depleting NK1.1 antibody. In contrast to the outcome in infected Rag2-/-γc mice, NK cell depletion 
did not impact bacterial clearance and both groups of mice cleared their infection by day 28 (Figure7D).  
 
Our experiments ruled out a role for NK cells in resolution, however the contribution of ILC3 to UTI 
immunity was still unclear. Interestingly, Rag2-/- mice can express IL-17 from “LTi-like cells” (group 3 
ILCs or ILC3s) following microbial stimulation, whereas Rag2-/-γc animals do not as they lack this cell 
population (46). Of the cytokines expressed in female and male mice during UTI, IL-17 exhibited one of 
the largest differences between the sexes, which persisted at 48 hours PI (Figure 2B-C). Thus, we 
hypothesized that IL-17 expression, early in infection, mediates bacterial clearance. To test whether IL-17 
is sufficient for bacterial clearance in male mice, we administered recombinant (r)IL-17 at the time of 
infection using two routes and two concentrations, or added additional rIL-17 intraperitoneal injections at 
4, 24, and 48 hours PI, and added rIL-17 into the bacterial inoculum (Figure S6A-B). rIL-17 did not 
impact UPEC colonization at 24 hours PI (Figure S6C). We followed infection by monitoring the 
number of animals with bacteriuria and observed that treatment did not improve the capacity of male mice 
to resolve UPEC infection in any condition (Figure S6D-F)  
 
Finally, to determine whether IL-17 is necessary for resolution of infection, we administered a single dose 
of α-IL-17 neutralizing antibody intravenously immediately prior to infecting female mice with one of our 
two isogenic UPEC strains and monitored bacteriuria over time. Notably, 8/12 mice treated with the α-IL-
17 antibody remained infected over 28-35 days, whereas 11/12 isotype-treated animals cleared bacteria 
with the expected kinetic (Figure 7E), supporting that this cytokine is necessary for resolution of UTI, 
however, in the absence of an inflammatory milieu, such as in male mice, it may not be sufficient to 
support bacterial clearance. 
 
Discussion  
Women experience UTI at a much higher frequency than men, although men develop more severe or 
chronic infections (9, 10). Anatomical differences between the sexes, such as urethra length, are often 
proposed as an explanation for the disproportional incidence of UTI in women, despite a lack of 
experimental evidence to support this hypothesis. Furthermore, this explanation fails to take into account 
the equivalently high frequency of infection in older men and women (7), and would instead suggest that 
urethra length changes in aged men, which is not the case (47). Finally, it does not address disparities in 
the outcome to infection between the sexes (8-10). Hypothesizing that sex-based differences in immunity 
influence response to UTI, we optimized a model to bypass anatomical differences to directly compare 
the innate and adaptive immune response in infected female and male mice. Female mice displayed a 
superior capacity to resolve infection compared to male mice and testosterone-treated female mice. 
Remarkably, IL-17 neutralization induced chronic infection in female mice. Interestingly, recombinant 
IL-17 supplementation in male mice was not sufficient to induce bacterial clearance. It is important to 
note that while 23 of 26 cytokines measured were increased in infected female bladders at 24 hours PI, 
only 7 were expressed above baseline in infected male bladders, and the magnitude of these changes was 
less than that of female mice. From these data, we conclude that while IL-17 is clearly necessary for 
resolution of infection, IL-17 alone is not sufficient to mediate clearance, perhaps due to an insufficiently 
pro-inflammatory micro-environment.  
 
IL-17 initiates many anti-bacterial pathways, including antimicrobial peptide and chemokine expression, 
recruitment and activation of neutrophils and monocytes, and potentially direct killing of infected cells 
(48-50). Notably, the majority of the small number of studies reporting IL-17 expression in UTI use 
pathogens other than UPEC, such as Proteus (51, 52), Streptococcus (53), Schistosoma (54), or Candida 
(55). Furthermore, these studies, as well as those using UPEC (56-58), report changes in IL-17 expression 
following vaccination or infection, but do not provide evidence that this cytokine supports or regulates 
host defense or bacterial clearance. Supporting our conclusion that IL-17 contributes to UTI resolution, 
bladder-associated bacterial CFU are higher in IL-17a-/- mice compared to wildtype animals at 3 and 4 
days PI, although whether these mice develop chronic infection is unknown (59). Th17 T cells, γδ T cells, 
neutrophils, and CD4+ ILC3 can express IL-17 (46, 50). Typically, γδ T cells express high levels of IL-17 
following infection or in the context of autoimmune inflammation (50). While γδ T cells are absent in 
Rag2-/- mice, ILCs are present (46), which may explain why female Rag2-/- mice resolve UTI with 
wildtype kinetics (32), whereas Rag2-/-γc animals remained chronically infected in this study.  
 
IL-17-mediated inflammation displays sex differences. In an allergic asthma model, male mice exhibit 
less inflammation compared to female mice and administration of testosterone leads to decreased 
numbers of IL-17-expressing Th17 T cells and an overall reduction in the level of inflammation associated 
with lung injury (60). Perhaps, most intriguingly, genetic variation in the Y chromosome imparts varying 
degrees of protection in a model of flu infection. In this study, infection of Y chromosome consomic 
C57BL/6 mice revealed that Y chromosome polymorphisms are associated with differences in the 
frequency of γδ T cells and IL-17 expression, which subsequently impact inflammatory response and 
disease severity in the lungs (61). 
 
IL-17 may also drive the initiation of pro-resolving type II immunity in the bladder. Indeed, in adipose 
tissue, the absence of γδ T cells or IL-17 leads to a reduction in IL-33 (62). In this tissue, TNFα and IL-17 
induce upregulation of IL-33, which in turn, controls thermoregulation and response to cold shock (62). 
Notably, TNFα is highly expressed in the bladder in the first hour following UPEC infection and, while 
IL-17 peaks at 24 hours PI, its expression is increased 10-100 fold over uninfected female animals 1-6 
hours PI (35), potentially inducing the increase in IL-33 observed in this study. Alternatively, we cannot 
exclude that differences in IL-33 expression are due to the extent of tissue damage between the sexes, 
however, this remains to be explored.  
The presence of a type II immune signature in UTI was unexpected. Type II immunity is typically 
associated with parasitic infections and non-infectious inflammatory diseases such as asthma and very 
few reports have focused on bacterial infection (42, 63, 64). However, the bladder retains metabolic waste 
until excretion and thus, repair of infected or damaged tissue must occur rapidly. Thus, we speculate that 
this signaling cascade acts to quickly induce type II immunity pathways to restore the important barrier 
function of the bladder. While this concept remains to be tested, emerging evidence supports that IL-17 
and IL-33 work in concert to maintain tissue homeostasis (62).  
 
The cytokine profile observed in female mice suggests that ILCs play a role in the induction of 
inflammation (ILC3) or reparative functions (ILC2) following infection. Notably, in the lung, ILCs, in 
female but not male mice, responded to IL-33 treatment by production of large amounts of IL-5 and IL-
13, and this cytokine response can be dampened by testosterone treatment (65, 66), suggesting that sex 
differences in the biology of ILCs influence immunity. This is an exciting new horizon for bladder 
mucosal immunity as, to the best of our knowledge, bladder-resident ILCs have not been reported. A 
single publication has described the presence of ILC2 in the urine of patients undergoing BCG 
immunotherapy for bladder cancer, however, their origin and function remain unknown (67). Activation 
and expansion of macrophages and ILCs following IL-33 expression would be expected to induce or 
amplify expression of IL-4, -5, -9, and -13, as well as CCL11, mediating eosinophil infiltration (68-70). 
Thus, eosinophils, while not required for bacterial clearance, likely play a role in another aspect of host 
defense, repair, or homeostasis. While this is an area that clearly requires further investigation, one 
possibility is that eosinophils amplify type II immunity supporting development of humoral responses 
following infection.  
 
What remains to be determined is the underlying cause of this differential cytokine response between 
female and male mice. Development of chronic UTI in male and testosterone-treated female mice 
supports that sex hormone levels play an essential role in the response to bacterial colonization. Although 
we ruled out that testosterone was aromatized to estrogen, and our results in castrated and estradiol-
supplemented animals support that testosterone plays a direct role in suppressing the immune response to 
UPEC infection, estrogen can also play a direct or indirect role in susceptibility to infection, particularly 
in older patients. Signaling via estrogen receptor α enhances IL-4 and IL-13 expression and polarization 
of myeloid cells towards an M2-like phenotype (71, 72). Estrogen treatment in vitro increases human β-
defensin 3 expression (73), although how this is mediated is unknown. Ovariectomized mice have higher 
bladder bacterial colonization compared to intact mice (73), however, this was not recapitulated in the 
surgical model comparing female and male UTI (27). One reason may be that, in addition to the method 
employed to infect mice (i.e., catheterization of female mice versus incision through the abdominal wall 
in both sexes), the mouse and bacterial strains differ between these two studies (19, 73). Notably, our 
study utilized one of the same mouse strains and the same bacterial strain as those used in Olsen et al., 
however, C57BL/6J mice remained chronically infected only in our study, suggesting that response to 
surgical manipulation may impact bacterial clearance (19).  
 
In sum, our study demonstrates, in a physiologically relevant model, that IL-17 specifically influences the 
innate response to bacterial infection in a sex-dependent manner. Interestingly, the first 24 hours of 
infection were critical in determining whether an animal would resolve infection. Whether the response to 
infection in this same time period in humans determines outcome remains to be seen, however our 
analysis of human samples revealed that a significant number of sex differences in immune gene 
expression, including players in the IL-17 - IL-33 axis, arise in the first 22 hours following E. coli-
induced immune responses in whole blood. Thus, our work may unlock the potential for fundamental 
research to better understand immunity in this underappreciated organ, by providing a valuable tool for 
the investigation of urogenital pathologies that display a sex difference between men and women beyond 
UTI, such as bladder cancer or interstitial cystitis, and support the development of sex-specific immune 
modulating therapies to improve the pronounced sex differences observed clinically in response to 
infection of the urinary tract.  
Methods 
Study approval 
This study was conducted using a preclinical mouse model in controlled laboratory experiments to test the 
hypothesis that the immune response to urinary tract infection differs between female and male animals. 
Animals were assigned to groups upon random partition into cages. In all experiments, a minimum of 3 
and a maximum of 12 animals made up an experimental group and all experiments were repeated 2-5 
times. Data were pooled before statistical analysis and outliers were identified using the Grubbs’ test 
(GraphPad QuickCalcs). In the case of an outlier in a parameter, all parameters measured in the 
corresponding mouse were excluded. As determined a priori, all animals having abnormal kidneys 
(atrophied, enlarged, white in color) at the time of sacrifice were excluded from all analyses, as 
previously we observed that abnormal kidneys negatively impact resolution of infection. Endpoints were 
determined prior to the start of experiments and researchers were not blinded to experimental groups.  
 
Ethics Statement  
Animal experiments were conducted in accordance with approval of protocol number 2012-0024 and 
2016-0010 by the Comité d’éthique en expérimentation animale Paris Centre et Sud and the Comités 
d'Ethique pour l'Expérimentation Animale Institut Pasteur (the ethics committee for animal 
experimentation), in application of the European Directive 2010/63 EU. In all experiments, mice were 
anesthetized by intraperitoneal injection of 100 mg/kg ketamine and 5 mg/kg xylazine and sacrificed 
either by cervical dislocation or carbon dioxide inhalation. Human data was from the Milieu Intérieur 
Project (https:// clinicaltrials.gov; identifier: NCT01699893) and was previously described (36). Briefly, 
publically available data (Dataset S1: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5776984/bin/pnas.1714765115.sd01.txt) (36) from 600 
healthy volunteers (as defined by inclusion/exclusion criteria) of mainland French origin from the ages of 
20-49 years, and stratified by sex were included in our analysis (74).   
 
Mice 
Female and male mice between the ages of 5-12 weeks were used in this study. C57BL/6J were obtained 
from Charles River Laboratories France, RAG2-/-γc were bred in house at Institut Pasteur, Paris.  
 
Urinary tract infection and determination of bacterial burden 
Female and male mice were anesthetized as above, catheterized transurethrally, and infected with 107 
colony forming units of UTI89-GFP-ampR or UTI89-RFP-kanR (32) in 50 µL PBS as previously 
described (12, 31). UTI89-GFP-ampR and UTI89-RFP-kanR infect with equal efficiency (32) and were 
used interchangeably, with the exception of experiments to detect bacteria by flow cytometry, in which 
only UTI89-RFP-kanR was used because the GFP signal is masked by autofluorescence in the bladder 
(32). 
 
Infection was monitored by examining bacterial growth from urine samples. Urine was collected every 2-
5 days and 2 µL were diluted directly into 8 µL PBS spotted on agar plates containing antibiotics as 
appropriate. The presence of any bacterial growth was counted as positive for infection. The limit of 
detection (LOD) for this assay is 500 bacteria per mL of urine. Mice were sacrificed at indicated 
timepoints, bladders homogenized in sterile PBS, serially diluted, and plated to determine CFU. The LOD 
for CFU is 20 or 30 bacteria per organ, depending upon the number of dilutions plated, and is indicated 
by a dotted line in graphs. All sterile organs are reported at the LOD. 
 
Flow cytometry 
Mice were sacrificed at indicated timepoints and the bladders removed. Single cell homogenates were 
prepared as previously described (31, 32). Briefly, minced bladders were incubated in 0.34 Units/mL 
Liberase TM (Roche) diluted in PBS at 37°C for 1 hour, with manual agitation every 15 minutes. 
Digested tissue was passed through a 100 µm filter (Miltenyi), washed, blocked with FcBlock (BD 
Biosciences), and immunostained (Supplemental Table 2). Samples were acquired on a BD Fortessa 
(BD Biosciences) and analyzed using FlowJo Version 10 software.  
 
Luminex MAP analysis  
Bladders were removed at 0, 24, and 48 hours PI and placed in 1 mL of cold PBS and homogenized with 
a handheld tissue grinder on ice or with a PreCellys24 bead mill homogenizer. 100 µL were removed to 
determine CFU and homogenates were clarified by microcentrifugation (13K, 4°C, 5 minutes) and stored 
at -20°C until analysis. After thawing, prior to analysis, samples were centrifuged a second time to 
remove remaining cell debris. All samples were assessed together to avoid inter-assay variability by 
Millipore Milliplex MAP Mouse Cytokine/Chemokine Magnetic Bead Panel, Premixed 32-Plex, 
according to the manufacturer’s recommendations (Merck Millipore). Cytokines with values less than the 
minimal detectable concentration +2 standard deviations (MinDC+2SD, manufacturer’s 
recommendations) in both female and male mice at 24 hours PI, the peak of cytokine expression (35), 
were removed prior to statistical analysis; these were IL-3, IL-7, IL-12p70, MIP1β, RANTES, and TNFα. 
 
Castration, hormone implantation, and determination of hormone levels 
5-7 week old male C57BL/6J mice were anesthetized and a small incision made in the scrotum. Testes 
were externalized, large vessels ligated, and the testes were removed. The incision was closed using 
VetBond glue. Control (mock) animals received an incision, the testes were exposed, and then the 
incision was sealed with VetBond. 17b-estradiol or placebo pellets (0.05 mg/pellet, cat # E-121 or C-111, 
respectively, Innovative Research of America) were placed under the back skin of mice 1 week after 
castration by trochar. Empty control and testosterone-filled implants were made according to (75). 
Briefly, silastic tubing (Dow Corning) containing 5 mM packed testosterone propionate (Sigma, Cat # 
86541), approximately 0.8-1 mg, were implanted under the skin of 6-7 week old female C57BL/6J mice 
through a small incision. Incisions were closed using 1-2 stitches with Vicryl sutures. Control (mock) 
animals received empty tubing. All mice were allowed to recover for one week after each manipulation. 
Plasma testosterone and estrogen levels were determined by ELISA following manufacturer’s instructions 
(ab108666 and ab108667, respectively, Abcam).  
 
Cell depletion, recombinant protein supplementation, and protein neutralization 
Cell depletion and cytokine neutralization were performed as follows:  
For SiglecF depletion, 10 µg/mouse α-SiglecF antibody (clone E50-2440, BD Pharmingen) or 10 
µg/mouse IgG2a isotype control (clone R35-95, BD Pharmingen) were delivered intraperitoneally in 100 
µL PBS (39) at the time of infection, and every 7 days for 3 weeks. For NK cell depletion, 100 µg/mouse 
α-NK1.1 (clone PK136, BioXcell) or 100 µg/mouse IgG2a isotype control (clone C1.18.4, BioXcell) 
were delivered intraperitoneally in 100 µL PBS. Mice received isotype control or depleting α-NK1.1 24 
hours prior to primary infection and then again on day 6, 13, and 20 post-primary infection. For IL-33 
neutralization, 3.6 µg/mouse α-IL-33 (catalog number AF3626, BioTechne/R&D Systems) or 3.6 
µg/mouse polyclonal goat IgG isotype control (catalog number AB-108-C, BioTechne/R&D Systems) 
were delivered intraperitoneally in 100 µL PBS (45). Mice received isotype control or neutralizing α-IL-
33 2 hours prior to primary infection and then again on day 1, 4, and 7 post-primary infection. For IL-33 
supplementation, mice received 2.5 ng recombinant IL-33 (equivalent to that measured in female mice at 
24 hours PI) (catalog number 3626-ML-010, BioTechne/R&D Systems) intravesically at the time of 
infection and 24 hours PI. For IL-17 supplementation, mice received 100 pg or 100 ng recombinant IL-17 
(catalog number 421-ML, BioTechne/R&D Systems) intravesically or intraperitoneally at the time of 
infection, or mice received 100 ng intraperitoneally at the time of infection, and 4, 24, and 48 hours PI. In 
this second experimental design, rIL-17 was also included in the bacterial inoculum at 100 ng/mL. For IL-
17 neutralization, 83.3-111 µg/mouse α-IL-17 (clone 50104, BioTechne/R&D Systems) or 83.3-111 
µg/mouse rat IgG2a isotype control (clone 54447, BioTechne/R&D Systems) were delivered 
intravenously in 100 µL PBS. Mice received a single injection of isotype control or neutralizing α-IL-17 
at the time of infection. 
 
Statistical analysis 
Statistical significance was performed in Prism 6 or Prism 8 for Mac OS X using the nonparametric 
Mann-Whitney test (two groups) or the nonparametric Kruskal-Wallis test with a Dunn's multiple 
comparison post-test (3 or more groups) for all data except cytokine analysis and human mRNA 
expression data. A p value of less than 0.05 was considered significant. Multiple testing correction (q) 
within analyses was performed using the Holm–Bonferroni method 
(https://jboussier.shinyapps.io/MultipleTesting/). Qlucore Omics Explorer 3.2 software was used to test 
statistical significance of cytokine protein expression data and human mRNA expression data after log-
transformation of the raw data and to calculate q-values (the false discovery rate adjusted p value) after 
log transformation of the values, using either a T-test or ANOVA as indicated. 
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Figures and Figure Legends  
 
Figure 1. 
 
 
Figure 1. Male mice do not resolve UTI following intravesical instillation. (A-B) 7 week old female 
and male C57BL/6J mice were infected with 107 CFU of UPEC strain UTI89-RFP-kanR or UTI89-GFP-
ampR. Graphs depict (A) the number of infected mice, determined by urine sampling, and (B) 
CFU/bladder. (C) Schematic of the experiment depicted in D: Female and male C57BL/6J mice were 
infected with 107 CFU of UPEC strain UTI89-GFP-ampR and bladder bacterial burden was determined 24 
hours post primary (1°) infection. At 29 days post-infection (PI), all animals were treated with antibiotics 
for 5 days, followed by a 7 day wash-out period. After determination that all mice had sterile urine, mice 
were challenged with 107 CFU UPEC strain UTI89-RFP-kanR and CFU in bladders determined at 24 
hours post challenge (2°) infection. (D) The graph shows bacterial CFU at 24 hours post primary or 
challenge infection in the bladder. A depicts representative data (n=10 female, n=9 male) from 1 of more 
than 5 experiments, red is female, blue is male. Data in B and D are pooled from 2-4 experiments, n=6-10 
mice/group in each experiment. Each dot represents one mouse, red denotes female mice and blue 
indicates male mice, lines are medians. Dotted lines depict the limit of detection of the assay, 20 
CFU/bladder. In B, **** p<0.0001, Kruskal-Wallis test comparing female to male at each timepoint, with 
Dunn's post-test to correct for multiple comparisons. In D, ** p<0.01, ns = not significant, Kruskal-Wallis 
test comparing 1° to 2° infection within a single sex and comparing 1° or 2° CFU between sexes, with 
Dunn's post-test to correct for multiple comparisons.  
  
Figure 2.  
 
Figure 2. Females exhibit a more robust cytokine response to E. coli than males. (A-C) Female and 
male mice were instilled with PBS or infected with 107 CFU of UPEC strain UTI89-RFP-kanR or UTI89-
GFP-ampR and sacrificed 24 or 48 hours PI. 32 cytokines were measured in homogenized bladders by 
Luminex assay. (A) The heat map shows unsupervised hierarchical clustering of the 21 significantly 
different analytes determined by ANOVA (false discovery rate (FDR) adjusted p value to correct for 
multiple testing; q<0.05, p and q values for each cytokine are shown in Table 1) among PBS-treated and 
UPEC-infected female and male mice. (B-C) Spider plots show absolute cytokine expression levels 
(pg/mL) on a log-scale at (B) 24 hours PI in PBS-treated (dotted lines) and UPEC-infected female (solid 
red lines) and male (solid blue lines) mice and (C) 48 hours PI in both sexes (solid red or blue lines) or in 
naïve, untreated female and male animals (dotted red or blue lines). Data are pooled from 4 experiments, 
n=5-7 mice per experiment. (D-E) Analysis was performed on a publically available dataset of the 
transcriptional response in whole blood after stimulation with heat-killed E. coli from 300 female and 300 
male healthy donors, aged 20-49 years old. (D) The PCA plot represents the variance among 275 genes 
that are significantly differently expressed between women (red dots, each dot is a donor) and men (blue 
dots, each dot is a donor) as determined by ANOVA, q<0.01. (E) The mRNA expression level in each 
donor for CXCL2, IL-8, IL-1α, and LIF was overlaid on the PCA plot shown in D) as a heat map, in 
which red represents higher gene expression and green represents lower gene expression. 
  
Figure 3.  
 
Figure 3. Immune cell infiltration is greater in female mice than male animals following UPEC 
infection. Female and male mice were infected with 107 CFU of UPEC UTI89-RFP-kanR for 24 or 48 
hours and bladders analyzed by flow cytometry. Figure S2 depicts gating strategies. Graphs depict (A) 
total CD45+ immune cells and (B-C) total specified immune cell populations at the depicted hours post-
infection (PI) in bladders, 0 hours PI = naïve mice. Data are pooled from 2-3 experiments, n=3-7 mice per 
experiment. Each dot represents one mouse, red denotes female mice and blue indicates male mice, lines 
are medians. * p<0.05, ** p<0.01, *** p<0.001, ns = not significant, Kruskal-Wallis test comparing 
female to male at each timepoint, with Dunn's post-test to correct for multiple comparisons.  
  
Figure 4.  
 
Figure 4. Immune cell populations contain more bacteria in female mice. Female and male C57BL/6J 
mice were infected with 107 CFU UPEC strain UTI89-RFP-kanR and bladders analyzed by flow 
cytometry. Figure S2 depicts gating strategies. (A-B) tSNE plots show total CD45+ immune cell 
populations at 24 hours PI from (A) a concatenated sample of 4 female and 4 male mice and (B) the same 
plot with conventionally gated populations overlaid. (C) UPEC+ cells from female (left) or male (right) 
bladders are shown using the same tSNE parameters in A-B. (D-E) Graphs show (D) the total number of 
specified immune cell populations containing UPEC and (E) the percentage of UPEC+ cells within the 
specified immune cell populations. Data are pooled from 2-4 experiments, n=4-5 mice per experiment. 
Each dot is one mouse, red dots depict female mice and blue dots are male mice, lines are medians. * 
p<0.05, ** p<0.01, **** p<0.0001, Mann-Whitney test. Analyses in this figure were corrected for 
multiple testing by Holm–Bonferroni method, all p<0.05 had q< 0.05.   
  
Figure 5.  
 
Figure 5. Testosterone treatment induces persistent infection in female mice. (A-E) 7-week old male 
C57BL/6J mice were mock-castrated (Mock), castrated, or castrated and supplemented with estradiol or 
placebo pellets and allowed to recover 1 week before infection. (C, F-L) Female mice were implanted 
with tubing containing testosterone (T tube) or empty tubing (Mock) and allowed to recover 1 week 
before infection. All mice were infected with 107 CFU UPEC strain UTI89-GFP-ampR or UTI89-RFP-
kanR. Graphs show (A) the number of infected male mice over time, (B) CFU/bladder 28 days PI in male 
mice, (C) testosterone levels in naïve and castrated (Castr) male mice; and naïve, empty tube (Mock), and 
testosterone-treated (T tube) female mice, (D) the number of infected male mice over time, (E) 
CFU/bladder 28 days PI in male mice, (F) the number of infected female mice over time, (G) 
CFU/bladder 24 hours PI in female mice, (H) CFU/bladder 28 days PI in female mice, (I) estrogen levels 
in naïve, empty tube (Mock), or testosterone-treated (T tube) female mice. (J) Spider plot shows cytokine 
expression 24 hours PI in mock and testosterone-treated female mice. (K) Heat map shows unsupervised 
hierarchical clustering of the 9 significantly different analytes between mock- and testosterone-treated 
female mice 24 hours PI, analyzed by T-test, FDR adjusted p value; q<0.15. Analyte p and q values are in 
Table 2. (L) Graphs show the number and percentage of eosinophils in bladders 24 hours PI. See Figure 
S3 for additional immune cell populations. Data are pooled from 2-4 experiments, n=4-10 mice/group in 
each experiment, except in A and F, which are a single experiments representative of 2-4 independent 
experiments. In B, C, E, G, H, I, L each dot is one mouse, lines are medians. In C, H, L, *** p<0.001, 
**** p<0.0001, Mann-Whitney test, FDR q=0.0009 to correct for multiple testing of immune populations 
analyzed in this figure and accompanying Figure S3. 
  
Figure 6. 
 
Figure 6. Female mice display characteristics of a type II immune response that is not suppressed 
by testosterone. (A-C) Female and male mice were infected with 107 CFU of UPEC UTI89-RFP-kanR 
and bladders analyzed at 24 hours PI. Graphs show (A) IL-33 protein levels in homogenized bladder, (B) 
IL-4Rα expression on bladder resident macrophages (Mf), and (C) the number of ILCs (CD90+ CD3- 
CD4- NK1.1- MHC II- CD11b-) in bladders. (D-F) Female mice were implanted with empty tubing 
(Mock) or slow release tubing containing testosterone (T tube) and allowed to recover 1 week before 
infection with 107 CFU UPEC strain UTI89-RFP-kanR. Graphs show (D) IL-33 protein levels in 
homogenized bladder tissue, (E) IL-4Rα expression on bladder resident macrophages, and (F) the number 
of ILCs in bladders. Data are pooled from 2-3 experiments, n=4-5 mice/group in each experiment. Each 
dot is one mouse, red dots depict female mice and blue dots are male mice, lines are medians. ns = not 
significant, * p< 0.05, ** p<0.01, *** p<0.001, **** p<0.0001 Mann-Whitney test. Analyses in this 
figure were corrected for multiple testing by Holm–Bonferroni method, all p<0.05 had q< 0.05.  
Figure 7. 
 
Figure 7. IL-17 is necessary for resolution of infection in female mice. (A) Female and male mice 
were infected with 107 CFU of UPEC strain UTI89-RFP-kanR and bladders analyzed by flow cytometry at 
24 hours PI. Graphs show (A) the number of CD3+ CD4+ T cells, CD3- NK1.1+ NK cells, γδ T cells, and 
CD4+ ILC3s (CD90+ CD25+ CD4+ CD3- NK1.1- MHC II- CD11b-) in bladders. (B) Female mice were 
implanted with empty tubing (Mock) or slow release tubing containing testosterone (T tube) and allowed 
to recover 1 week before infection with 107 CFU UPEC strain UTI89-RFP-kanR. Graphs show the 
number of CD3+ CD4+ T cells, CD3- NK1.1+ NK cells, γδ T cells, and CD4+ ILC3s (CD90+ CD25+ CD4+ 
CD3- NK1.1- MHC II- CD11b-) in bladders. (C-E) Graphs show the number of infected female mice, 
determined by urine sampling, over time in (C) wildtype or RAG2-/-γc mice, (D) mice treated with isotype 
or α-NK1.1-depleting antibody, (E) mice treated with α-IL-17 neutralizing antibody. (A-B) Data are 
pooled from 2-3 experiments, n=4-5/group in each experiment. Each dot is one mouse, red dots depict 
female mice and blue dots are male mice, lines are medians. (C-E) Graphs are representative experiments, 
n=6-12 mice per experiment, 2-3 experiments each. * p<0.05, ** p<0.01, analyses in (A) Kruskal-Wallis 
test comparing female naïve to male naïve, female naïve to female infected, male naïve to male infected 
and female infected to male infected, with Dunn's post-test to correct for multiple comparisons, (B) 
Mann-Whitney test with correction for multiple testing by Holm–Bonferroni method, all p<0.05 had q< 
0.05. 
 
  
Table 1: Analytes defining the response to infection, compared to PBS instillation, at 24 hours 
 PBS vs UTI Female 
mice*# 
PBS vs UTI Male 
mice‡ 
PBS vs UTI Both sexes° 
Analyte p-value q-value p-value q-value p-value q-value 
LIF 3.17E-12 8.25E-11 2.51E-05 6.52E-04 6.82E-17 1.77E-15 
CXCL1 7.26E-11 9.44E-10 1.25E-02 4.64E-02 4.63E-12 3.01E-11 
IL-17 1.13E-10 9.79E-10 2.81E-03 1.46E-02 1.80E-12 1.56E-11 
IL-6 7.79E-10 5.06E-09 1.38E-04 1.79E-03 7.68E-14 9.98E-13 
CSF1 3.13E-09 1.63E-08   7.94E-11 3.44E-10 
CCL2 3.97E-08 1.72E-07 2.19E-04 1.90E-03 3.16E-11 1.64E-10 
CCL11 5.06E-07 1.88E-06   6.65E-07 1.73E-06 
CSF3 1.07E-06 3.49E-06 6.35E-04 4.13E-03 1.73E-08 6.41E-08 
CXCL10 2.56E-06 7.38E-06   7.76E-05 1.44E-04 
VEGF 6.51E-06 1.69E-05   1.44E-02 1.79E-02 
IL1α 2.51E-05 5.93E-05   3.18E-04 4.86E-04 
CXCL9 3.88E-05 8.41E-05   6.73E-05 1.44E-04 
IL-15 6.04E-05 1.21E-04   7.51E-05 1.44E-04 
IL-4 1.02E-04 1.90E-04   1.43E-05 3.39E-05 
IL-2 2.24E-04 3.89E-04   2.18E-03 3.02E-03 
IL-10 6.57E-04 1.07E-03   2.21E-03 3.02E-03 
CCL3 9.38E-04 1.36E-03   1.25E-02 1.63E-02 
IL1β 8.93E-04 1.36E-03 9.90E-03 4.29E-02 1.10E-07 3.58E-07 
CSF2 2.05E-03 2.80E-03   1.29E-04 2.10E-04 
CXCL2 3.34E-03 4.34E-03   8.86E-05 1.54E-04 
IL-13 1.58E-02 1.96E-02     
IL-5 2.30E-02 2.72E-02   1.87E-07 5.39E-07 
IFNγ 3.20E-02 3.62E-02     
 
*Values are ordered by decreasing q-value for analytes that are statistically significantly different 
between PBS- and UPEC-instilled female mice. q-values are the false discovery rate adjusted p value.  
# p-value and q-value determined by T-test between PBS-treated and UPEC-infected female mice 
‡ p-value and q-value determined by T-test between PBS-treated and UPEC-infected male mice 
° p-value and q-value determined by ANOVA among PBS-treated female mice, UPEC-infected female 
mice, PBS-treated male mice, and UPEC-infected male mice 
The absence of a value indicates that the analyte was not different between PBS and UPEC-infected 
animals in the group indicated at the top of the column 
 
  
Table 2: Analytes defining the response to infection in female mice treated with mock tubes 
compared to testosterone tubes at 24 hours 
Mock vs Testosterone tube Female mice* 
Analyte p-value q-value 
IL-13 2.21E-03 5.75E-02 
VEGF 7.72E-03 6.69E-02 
IL-2 5.16E-03 6.69E-02 
IL-9 1.14E-02 7.44E-02 
IL-4 1.55E-02 8.08E-02 
IL-12p40 2.67E-02 1.07E-01 
IL1α 3.31E-02 1.07E-01 
CCL11 3.23E-02 1.07E-01 
IL1β 4.12E-02 1.19E-01 
 
*Values are ordered by decreasing q-value for analytes that are statistically significantly different 
between mock- and testosterone-treated female mice (q<0.15, q-values are the false discovery rate 
adjusted p value.) 
 
  
